Tag: Xarleto
Rivaroxaban OK for Stroke Prevention in Cancer Patients
Safety, efficacy in cancer patients similar to the general population
ACC: Rivaroxaban Beats Aspirin for Lower Risk of Recurrent VTE
Low dose cuts risk in equipoise for continued anticoagulation; rate of bleeding similar to aspirin
Higher Bleeding Risk Seen With Rivaroxaban Versus Dabigatran
Increase in risk of intracranial hemorrhage, major GI bleeding in a-fib patients taking rivaroxaban
DAPT Use Variable in Patients With A-Fib at Risk of Stroke
Dual antiplatelet therapy used in variable manner; most patients remain on study drug after PCI